Navigation Links
Roche Submits Application for Clearance of Chlamydia and Gonorrhoeae Test
Date:5/6/2011

PLEASANTON, Calif., May 6, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has filed for FDA clearance of its Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) tests.

When cleared this standardized and fully automated test will help physicians detect and subsequently treat patients with the disease. Clinical trial data will be presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID, May 7-13, Milan, Italy) demonstrating the effectiveness of the assay using multiple sample types. The test is suitable for use in a broad range of settings and laboratories. Roche was the first company to offer a Polymerase Chain Reaction (PCR) based CT/NG test. This latest offering builds on that legacy while introducing novel features that meet customer needs.

"We are pleased to submit for review this innovative test that will address a key medical need," said Paul Brown, Ph.D., Head of Roche Molecular Diagnostics. "With this test Roche will expand the menu on the recently approved cobas 4800 platform currently in use in the US for HPV testing and so continue to improve the workflow for laboratories."

About ChlamydiaChlamydia is the most common bacterial Sexually Transmitted Disease (STD) with the highest prevalence among youth. Routine screening for chlamydial infection in young women has been demonstrated to reduce infection rates and the long-term consequences of untreated disease, as well as lowering the cost of this STD to society.  The Center for Disease Control recommends annual Chlamydia trachomatis screening for all sexually active females under 25 years old and additional testing for pregnant women and those with risk factors.

About cobas 4800 CT/NG testThe test runs on the fully automated cobas 4800 platform which was recently introduced in the US concurrent with the approval of Roche's HPV test.

The cobas CT/NG  test is a qualitative in-vitro test for the detection of CT/NG in patient specimens. The test utilizes amplification of target DNA by the Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the detection of CT/NG in a single analysis. The test, CE marked in 2009, is currently available in numerous countries around the world.

The cobas 4800 System is designed to deliver new standards in laboratory testing efficiency and medically relevant diagnostic information.  

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80'000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.Roche Molecular SystemsPhone: 888-545-2443
'/>"/>

SOURCE Roche
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rochester Medical Reports Second Quarter Results
2. Rochester Medical Announces Second Quarter 2011 Earnings Conference Call Thursday, May 5, 2011
3. Roche Launches EMR Interface for VA to Facilitate Diabetes Management
4. Rochester Medical Completes Acquisition of Laprolan
5. MITs Koch Institute to use Roche LightCycler 480 System to Help Advance Cancer Research
6. Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation
7. Janet Hammond Joins Roche as Vice President, Translational Medicine - Virology
8. Cellular Dynamics International and Roche Transition Early Access Collaboration into a Standard Supply Agreement Ahead of Schedule
9. Roche Teams with Womack Army Medical Center to Become First IVD Manufacturer approved for Remote Network Connectivity with DOD
10. Rochester Medical Reports First Quarter Results and Recent Developments
11. Rochester Medical Announces First Quarter 2011 Earnings Conference Call Tuesday, January 25, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... May 3, 2016  As a teenager, an active ... fever, which damaged his heart. He continued enjoying sports ... June 2013, Shepherd,s heart was giving out and he ... June 20, 2013, the Mesa, Arizona ... (TAH-t). Like a heart transplant, the SynCardia TAH-t is ...
(Date:5/3/2016)... 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is celebrating Hepatitis ... of two patients who tell their personal story and encourage those at risk to get ... Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... is excited to announce the launch of its Mediceutical line of products, a line ... variety of clinical conditions. Founded in 2013, Forté spent more than two years researching ... http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... a2z, Inc. is pleased ... Canadian Association for Enterostomal Therapy (CAET) will be utilizing powerful and innovative technology ... attendees and exhibitors for the 2016 WOCN Society & CAET Joint Conference—which is ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... Washington Wellness ... well-being for central New Jersey residents. What started out as an idea to ... seeking an integrated approach to healthcare. , Developed by Dr. David Swanekamp, Chiropractic ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... breastfeeding for nursing mothers. The company’s patented technology, The Smart Breastfeeding Meter, is ... company announced that the technology is now available for purchase at Target.com ...
(Date:5/4/2016)... ... May 04, 2016 , ... Natalie Jill ... local company MitoXcell in preparation of the launch of her new book: Natalie Jill’s ... is a nutritional guide designed to jump start a new healthy lifestyle featuring simple ...
(Date:5/4/2016)... ... ... Advanced Spine & Sport Medical Rehabilitation Center, which is renowned for its ... seminar on stem cell injections. The seminar is scheduled for Wednesday, May 18, from ... Suite 110, Ventura, CA. There are only 10 seats available. , “The purpose ...
Breaking Medicine News(10 mins):